Afisi Ismaila

7.3k total citations · 4 hit papers
127 papers, 5.0k citations indexed

About

Afisi Ismaila is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, Afisi Ismaila has authored 127 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Pulmonary and Respiratory Medicine, 62 papers in Physiology and 16 papers in Epidemiology. Recurrent topics in Afisi Ismaila's work include Chronic Obstructive Pulmonary Disease (COPD) Research (86 papers), Asthma and respiratory diseases (61 papers) and Inhalation and Respiratory Drug Delivery (38 papers). Afisi Ismaila is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (86 papers), Asthma and respiratory diseases (61 papers) and Inhalation and Respiratory Drug Delivery (38 papers). Afisi Ismaila collaborates with scholars based in Canada, United States and United Kingdom. Afisi Ismaila's co-authors include Lehana Thabane, Rong Chu, Ji Cheng, Lora Giangregorio, Jinhui Ma, Lorena P Rios, Reid Robson, Marroon Thabane, Charles H. Goldsmith and Pasqualina Santaguida and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Internal Medicine and CHEST Journal.

In The Last Decade

Afisi Ismaila

117 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A tutorial on pilot studies: the what, why and how

2010 2.1k citations Lehana Thabane, Afisi Ismaila et al. profile →
Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

2008 560 citations Afisi Ismaila et al. profile →
Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program

2011 559 citations Afisi Ismaila et al. profile →
<p>Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review</p>

2020 240 citations Ike Iheanacho, Shiyuan Zhang et al. International Journal of COPD profile →

Peers

Countries citing papers authored by Afisi Ismaila

Since Specialization

Citations

This map shows the geographic impact of Afisi Ismaila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Afisi Ismaila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Afisi Ismaila more than expected).

Fields of papers citing papers by Afisi Ismaila

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Afisi Ismaila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Afisi Ismaila. The network helps show where Afisi Ismaila may publish in the future.

Co-authorship network of co-authors of Afisi Ismaila

This figure shows the co-authorship network connecting the top 25 collaborators of Afisi Ismaila. A scholar is included among the top collaborators of Afisi Ismaila based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Afisi Ismaila. Afisi Ismaila is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study 2024 ·International Journal of COPD ·Claus Vogelmeier, Kai Michael Beeh, (unknown), Nils Kossack, (unknown), Jing Claussen, Chris Compton, Stephen G. Noorduyn, Afisi Ismaila, (unknown)	3
2	Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study 2024 ·BMJ Open Respiratory Research ·Kieran Rothnie, Robert Wood, (unknown), Victoria Banks, (unknown), (unknown), (unknown), Chris Compton, Raj Kumar Sharma, David Halpin, Afisi Ismaila, Claus Vogelmeier	2
3	Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B ₂ -agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study 2024 ·BMJ Open ·(unknown), Victoria Banks, (unknown), Robert Wood, (unknown), (unknown), Chris Compton, Afisi Ismaila	0
4	Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians 2024 ·Respiratory Research ·Katrin Haeussler, Afisi Ismaila, (unknown), Stephen G. Noorduyn, Nathan Green, Chris Compton, Lehana Thabane, Claus Vogelmeier, David Halpin	1
5	Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany 2024 ·International Journal of COPD ·Kai Michael Beeh, Kieran Rothnie, Jing Claussen, (unknown), (unknown), Thomas Wilke, (unknown), Chris Compton, Afisi Ismaila	1
6	PCR255 Adherence to Single and Multiple Inhaled Triple Therapies in Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany, Considering Different Definitions 2023 ·Value in Health ·(unknown), Kieran Rothnie, Stephen G. Noorduyn, Jonathan C. Claussen, (unknown), Nils Kossack, Linda Richter, Claus Vogelmeier, Kai Michael Beeh, Raj Kumar Sharma, Chris Compton, Afisi Ismaila	1
7	Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study 2023 ·International Journal of COPD ·(unknown), (unknown), Takeo Ishii, Robert Wood, (unknown), Hannah Wallis, (unknown), (unknown), (unknown), (unknown), Kieran Rothnie, Afisi Ismaila	7
8	Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study 2023 ·Respiratory Research ·Afisi Ismaila, Kieran Rothnie, Robert Wood, Victoria Banks, (unknown), (unknown), Chris Compton, Raj Kumar Sharma, (unknown), (unknown), David Halpin	8
9	Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England 2023 ·International Journal of COPD ·(unknown), (unknown), Victoria Banks, Robert Wood, (unknown), (unknown), (unknown), (unknown), Chris Compton, Kieran Rothnie, Felix Herth, Jennifer K Quint, Afisi Ismaila	0
10	Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England 2023 ·International Journal of COPD ·(unknown), (unknown), Victoria Banks, Robert Wood, (unknown), (unknown), (unknown), (unknown), Chris Compton, Kieran Rothnie, Felix Herth, Jennifer K Quint, Afisi Ismaila	0
11	Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review 2023 ·International Journal of COPD ·(unknown), (unknown), Ike Iheanacho, Kieran Rothnie, Chris Compton, Afisi Ismaila	1
12	Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain 2022 ·International Journal of COPD ·(unknown), (unknown), Afisi Ismaila, Antoni Sicras‐Mainar, Aram Sicras-Navarro, Cruz González, (unknown), (unknown), (unknown)	1
13	Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Dual Therapy in a Primary Care Setting in England 2022 ·International Journal of COPD ·(unknown), Victoria Banks, (unknown), Robert Wood, (unknown), (unknown), Chris Compton, (unknown), Afisi Ismaila	1
14	Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting 2022 ·International Journal of COPD ·David Halpin, Kieran Rothnie, Victoria Banks, (unknown), Chris Compton, Robert Wood, (unknown), (unknown), (unknown), (unknown), (unknown), Raj Kumar Sharma, Afisi Ismaila, Claus Vogelmeier	31
15	Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial 2022 ·International Journal of COPD ·David Halpin, (unknown), (unknown), Alan Martin, Dhvani Shah, Dawn Midwinter, Kai Michael Beeh, Janwillem Kocks, Paul Jones, Chris Compton, Nancy Risebrough, Afisi Ismaila	10
16	Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis 2022 ·Advances in Therapy ·Afisi Ismaila, Katrin Haeussler, (unknown), Vanita Tongbram, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Chris Compton, Claus Vogelmeier, David Halpin	7
17	Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England 2021 ·International Journal of COPD ·Leah B. Sansbury, Robert Wood, (unknown), (unknown), Afisi Ismaila	6
18	COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners 2018 ·International Journal of COPD ·Wilhelmine Meeraus, Robert Wood, (unknown), Tim Holbrook, Geoffray Bizouard, (unknown), (unknown), Gaëlle Nachbaur, Sarah Landis, Yogesh Punekar, B. Aguilaniu, Afisi Ismaila	16
19	The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, Canada 2017 ·Canadian Respiratory Journal ·Tam Dang‐Tan, Shiyuan Zhang, (unknown), (unknown), Afisi Ismaila, Julie Vaillancourt, (unknown), Richard H. Stanford, Xiwu Lin, Gilbert Nadeau, (unknown), Daria Parsons, John S. Sampalis	5
20	Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model 2016 ·Medical Decision Making ·Andrew Briggs, Timothy Baker, Nancy Risebrough, Mike Chambers, Sebastian Gonzalez‐McQuire, Afisi Ismaila, Alex Exuzides, Chris Colby, Maggie Tabberer, Hana Muellerova, Nicholas Locantore, Maureen Rutten‐van Mölken, David A. Lomas	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact